Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives

The main protease (M(pro)) plays a pivotal role in the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target. Disruption of the catalytic activity of M(pro) produces a detrimental effect on the course of the infection, making th...

Descripción completa

Detalles Bibliográficos
Autores principales: Citarella, Andrea, Dimasi, Alessandro, Moi, Davide, Passarella, Daniele, Scala, Angela, Piperno, Anna, Micale, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647625/
https://www.ncbi.nlm.nih.gov/pubmed/37759739
http://dx.doi.org/10.3390/biom13091339
Descripción
Sumario:The main protease (M(pro)) plays a pivotal role in the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target. Disruption of the catalytic activity of M(pro) produces a detrimental effect on the course of the infection, making this target one of the most attractive for the treatment of COVID-19. The current success of the SARS-CoV-2 M(pro) inhibitor Nirmatrelvir, the first oral drug for the treatment of severe forms of COVID-19, has further focused the attention of researchers on this important viral target, making the search for new M(pro) inhibitors a thriving and exciting field for the development of antiviral drugs active against SARS-CoV-2 and related coronaviruses.

Ejemplares similares